Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.
about
Pirin downregulation is a feature of AML and leads to impairment of terminal myeloid differentiationGenomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid LeukemiaDeferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavengingThe NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells.Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemiaNF-κB p65 repression by the sesquiterpene lactone, Helenalin, contributes to the induction of autophagy cell deathCytoplasmic FANCA-FANCC complex interacts and stabilizes the cytoplasm-dislocalized leukemic nucleophosmin protein (NPMc)Gene mutations and molecularly targeted therapies in acute myeloid leukemia.Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicCytoplasmic nucleophosmin has elevated T199 phosphorylation upon which G2/M phase progression is dependent.Expression of nucleophosmin/NPM1 correlates with migration and invasiveness of colon cancer cells.Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.Role of nucleophosmin in acute myeloid leukemia.Pharmacogenomics in acute myeloid leukemia.Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD.Analogue peptides for the immunotherapy of human acute myeloid leukemia.Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology.Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.The importin-alpha/nucleophosmin switch controls taspase1 protease function.The level of glycolytic metabolism in acute myeloid leukemia blasts at diagnosis is prognostic for clinical outcome.Benznidazole modulates cell proliferation in acute leukemia cells.
P2860
Q22001531-33CE75D1-7FA3-4827-90EE-978B97487899Q26796514-8873CDE1-4E15-42EE-96F3-7BE2E4C2835BQ34032208-DF144585-0E1A-4C12-8E60-311C65DBD916Q34176804-9BCC0A94-4FCD-4C61-8E82-B8E371658EC1Q34316768-C5F7963E-92A2-4696-A1C1-AB30A0C77F85Q34333336-CC2B8E2E-9300-49AC-BBCE-E3026C835926Q34333634-B76FFE94-1CAA-43A7-BE2C-EAF4CA0FA85CQ34647741-52B9411D-13EC-4AD0-AD92-307D42DACD65Q34755985-024956EC-6E33-4214-98E9-BF2BC8516556Q34817365-8EC70328-735C-43E0-9745-CCD6D636EE85Q35796956-0459A358-BADA-4DEE-A743-BF432A227E41Q36116345-4D8B507B-E47F-4748-8D00-6AB646C84114Q37514846-EABF1809-3F95-4AF4-A77C-89829B42A147Q37598941-18372A2C-7B83-4E68-8C5F-B3945818E44EQ37627876-3EAF8E05-82C2-4724-9809-B820DCA56B34Q38289289-57EA4AF0-EC38-43D1-8A36-D9BC22DEE4C5Q38599586-59D70AAC-8DAB-4699-AF5A-0ADB887B9128Q39129437-1D881014-18B9-4457-9BAA-2D2AC1FEC624Q39450821-7218DDD9-8DF8-45E9-920E-2F1861478FD8Q39574027-2DDE0456-DBE2-4C63-B775-CFF6677BFA32Q39642198-51EB1C1B-FC15-47BF-B2DC-B43F7A72EAF9Q45071683-F1B5A646-7F24-4B15-82F2-B2F71715581C
P2860
Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Increase sensitivity to chemot ...... n AML carrying NPM1 mutations.
@ast
Increase sensitivity to chemot ...... n AML carrying NPM1 mutations.
@en
Increase sensitivity to chemot ...... n AML carrying NPM1 mutations.
@nl
type
label
Increase sensitivity to chemot ...... n AML carrying NPM1 mutations.
@ast
Increase sensitivity to chemot ...... n AML carrying NPM1 mutations.
@en
Increase sensitivity to chemot ...... n AML carrying NPM1 mutations.
@nl
prefLabel
Increase sensitivity to chemot ...... n AML carrying NPM1 mutations.
@ast
Increase sensitivity to chemot ...... n AML carrying NPM1 mutations.
@en
Increase sensitivity to chemot ...... n AML carrying NPM1 mutations.
@nl
P2093
P50
P356
P1433
P1476
Increase sensitivity to chemot ...... n AML carrying NPM1 mutations.
@en
P2093
G Martinelli
I Defilippi
I Iacobucci
M Pautasso
R Catalano
P2860
P2888
P304
P356
10.1038/LEU.2008.68
P577
2008-04-10T00:00:00Z
P5875
P6179
1019435949